Literature DB >> 9398858

Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome.

C T Dolphin1, A Janmohamed, R L Smith, E A Shephard, I R Phillips.   

Abstract

Individuals with primary trimethylaminuria exhibit a body odour reminiscent of rotting fish, due to excessive excretion of trimethylamine (TMA; refs 1-3). The disorder, colloquially known as fish-odour syndrome, is inherited recessively as a defect in hepatic N-oxidation of dietary-derived TMA and cannot be considered benign, as sufferers may display a variety of psychosocial reactions, ranging from social isolation of clinical depression and attempted suicide. TMA oxidation is catalyzed by flavin-containing mono-oxygenase (FMO; refs 7,8), and tissue localization and functional studies have established FMO3 as the form most likely to be defective in fish-odour syndrome. Direct sequencing of the coding exons of FMO3 amplified from a patient with fish-odour syndrome identified two missense mutations. Although one of these represented a common polymorphism, the other, a C-->T transition in exon 4, was found only in an affected pedigree, in which it segregated with the disorder. The latter mutation predicts a proline-->leucine substitution at residue 153 and abolishes FMO3 catalytic activity. Our results indicate that defects in FMO3 underlie fish-odour syndrome and that the Pro 153-->Leu 153 mutation described here is a cause of this distressing condition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398858     DOI: 10.1038/ng1297-491

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  59 in total

1.  Biochemical and molecular studies in mild flavin monooxygenase 3 deficiency.

Authors:  J Zschocke; E Mayatepek
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  A nonsense mutation in the FMO3 gene underlies fishy off-flavor in cow's milk.

Authors:  Anne Lundén; Stefan Marklund; Victoria Gustafsson; Leif Andersson
Journal:  Genome Res       Date:  2002-12       Impact factor: 9.043

3.  Clinical utility gene card for: trimethylaminuria.

Authors:  Elizabeth A Shephard; Eileen P Treacy; Ian R Phillips
Journal:  Eur J Hum Genet       Date:  2011-11-30       Impact factor: 4.246

4.  Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.

Authors:  Makiko Shimizu; Charles K Allerston; Elizabeth A Shephard; Hiroshi Yamazaki; Ian R Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

5.  Drug metabolism and pharmacogenetics: the British contribution to fields of international significance.

Authors:  John Caldwell
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

6.  Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs.

Authors:  Callum R Nicoll; Gautier Bailleul; Filippo Fiorentini; María Laura Mascotti; Marco W Fraaije; Andrea Mattevi
Journal:  Nat Struct Mol Biol       Date:  2019-12-23       Impact factor: 15.369

7.  Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide.

Authors:  Lisbeth K Siddens; Sharon K Krueger; Marilyn C Henderson; David E Williams
Journal:  Biochem Pharmacol       Date:  2014-02-19       Impact factor: 5.858

8.  Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk.

Authors:  W Zhu; J A Buffa; Z Wang; M Warrier; R Schugar; D M Shih; N Gupta; J C Gregory; E Org; X Fu; L Li; J A DiDonato; A J Lusis; J M Brown; S L Hazen
Journal:  J Thromb Haemost       Date:  2018-08-09       Impact factor: 5.824

9.  Trimethylamine and odorous sweat.

Authors:  S C Mitchell; R L Smith
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Aryl hydrocarbon receptor-dependent induction of flavin-containing monooxygenase mRNAs in mouse liver.

Authors:  Trine Celius; Steven Roblin; Patricia A Harper; Jason Matthews; Paul C Boutros; Raimo Pohjanvirta; Allan B Okey
Journal:  Drug Metab Dispos       Date:  2008-09-02       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.